50 Women to Watch
In today’s Wall Street Journal their Journal Report “The 50 Women to Watch” profiled 50 extraordinary women. While lists of this type are always somewhat subjective Diabetic Investor believes there is one woman who didn’t make the list but deserved to be included. Missing from the list was Ginger Graham CEO of Amylin Pharmaceuticals (NADAQ: AMLN). To state that Ms. Graham has done an outstanding job at Amylin is a serve injustice.
Since taking over the CEO spot on September 1, 2003 Ms. Graham helped transform Amylin from a developmental stage company to a first class organization with two first in class drugs, Symlin and Byetta. Amylin also has rich pipeline of drug candidates, the most promising being the once-a-week version of Byetta which will be a paradigm shifting drug when it comes to market sometime in late 2008 or early 2009.
Realizing that Amylin’s future is more than having approved drugs and solid drugs under development, Ms. Graham has assembled one of the finest and most talented group of people to work at Amylin.
It should not go unnoticed that shares of Amylin have risen nearly 60% since Ms. Graham became CEO and while she has already announced plans to leave Amylin in 2007, she has left the company in excellent shape for even greater growth. Diabetic Investor has long believed Amylin to be the most valuable property in the diabetes sector and in no small part Ms. Graham is a key reason why we feel this way.
As we mentioned earlier lists such as these are always subjective and surly there were other deserving women besides Ginger Graham who did not make it. However there is no disputing that Ginger Graham has done an outstanding job at Amylin and Diabetic Investor for one believes Ms. Graham deserves a great deal of credit.